| | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| |
| | ||||||||||||||||||||||||||||||||||||||||||
| | ||||||||||||||||||||||||||||||||||||||||||||
| | | The Pancreatic Cancer Stock Could Soon Be in Play
For the most part, biotech stocks have had a banner year. Until about a week ago, the bellwether biotech ETF iShares NASDAQ Biotechnology Index (NASDAQ - IBB) was up nearly 50% year to date. Then came the uncertainty of the government shutdown and looming budget showdown. This uncertainty prompted sales of biotech winners en masse last week, as investors elected to take profits - and quickly, but primarily in larger stocks rather than their small-cap brethren.
Following the sale of the larger-cap biotechs, we sense a tide is shifting toward the purchase of small-cap biotechs, and pancreatic cancer treatment-focused ones in particular. Nearly 45,000 Americans are diagnosed with pancreatic cancer each year. Pancreatic cancer is also one of the deadliest of all cancers, accounting for 38,000 deaths annually. In fact, the overall survival rate is also one of the lowest of all forms of cancer.
Currently, there are only three drugs approved for treatment of the disease. But there are some catalysts ahead that could drive this small-cap biotech stock meaningfully higher.
To read more click here >> or visit http://www.thestockjunction.com
These Stocks Are All Treat And No Trick
Since 1989, when I entered the investment industry, my perspective of life has revolved around stocks and the stock market. For example, late last week I noticed a press release from The Hershey Co. (NYSE - HSY) that announced its first new line of candy in 30 years (unrelated to acquisitions). It reminded me that Halloween is around the corner and that it might be an opportune time to profile a stock that is well-positioned to benefit from both the Halloween and year-end holiday season. Or, in other words, maybe now is the time to highlight a stock primed for a short-term trade.
Alas, while there is no sub-$5 stock that is a pure play in this sector, I did find a sub-$1 stock whose larger parent is a microcap stock that fits the bill nicely. Plus, considering that its majority-owned subsidiary is also publicly traded, investors get two stocks for the price of one.
Rocky Mountain Chocolate Factory, Inc. (NASDAQ - RMCF - $12.56) is an international franchiser, confectionery manufacturer and retail operator in the United States, Canada and the United Arab Emirates. The company manufactures an extensive line of premium chocolate candies and other confectionery products. Its revenues are derived from three principal sources: sales to franchisees and others of chocolates and other confectionery products it manufactures; the collection of initial franchise fees and royalties from franchisees' sales; and sales at company-owned stores of chocolates and other confectionery products.
To read more click here >> or visit http://www.thestockjunction.com
| | | ||||||||||||||||||||||||||||||||||||||||
|
|
| |
|
| | | ||
| | ||||||
No comments:
Post a Comment
Keep a civil tongue.